Literature DB >> 28056528

Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations.

Zhiping Guo1, Linhua Yang1, Xiuyu Qin1, Xiue Liu1, Yaofang Zhang1.   

Abstract

Hemophilia A (HA) is an X-linked bleeding disorder caused by heterogeneous mutations in the factor VIII gene ( F8). Our aim is to identify the causative mutations in a large HA cohort from China. We studied 216 unrelated HA families. Molecular analyses of F8 were performed using a combination of molecular techniques, including polymerase chain reaction, direct sequencing, and multiplex ligation-dependent probe amplification. The deleterious consequences of the unreported missense mutations were evaluated using various bioinformatics approaches. Causative mutations in F8 were identified in 209 families, intron 22 inversion (Inv22) was identified in 89 severe families, and intron 1 inversion (Inv1) was positive in 5 severe families; 95 mutations were detected among 115 noninversion families, of which 42 were novel, including 29 null variations and 13 missense mutations for which causality was demonstrated via bioinformatics. Among the 53 previously reported mutations, more nonsense (5 of 9) and missense (10 of 26) mutation sites were found to occur at Arginine (Arg) sites and multiple small deletions/insertions (5 of 10) located within the poly-A runs of the B domain. The majority of these sequence variants frequently recurred in the database. The odds ratios for the likelihood of developing inhibitors significantly increased in the presence of nonsense mutation. Our F8 defect spectrum was heterogeneous. Small deletions/insertions in the poly-A runs of the B domain and nonsense and missense mutations at Arg sites were identified as mutation hot spots. Nonsense mutation increased the risk of developing inhibitors.

Entities:  

Keywords:  China; bioinformatics; coagulation factor VIII gene; hemophilia A; inhibitors; mutation

Mesh:

Substances:

Year:  2017        PMID: 28056528      PMCID: PMC6714629          DOI: 10.1177/1076029616687848

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

1.  F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China.

Authors:  Jie Sun; Zekun Li; Kun Huang; Di Ai; Gang Li; Xingjuan Xie; Hao Gu; Guoqing Liu; Yingzi Zhen; Zhenping Chen; Runhui Wu
Journal:  Res Pract Thromb Haemost       Date:  2022-06-08

2.  Screening of Intron 1 Inversion of the Factor VIII Gene in 130 Patients with Severe Hemophilia A from a Pakistani Cohort.

Authors:  Azhar Sattar; Shabbir Hussain; Muhammad Ikram Ullah; Saqib Mahmood; Shahida Mohsin
Journal:  Turk J Haematol       Date:  2017-03-15       Impact factor: 1.831

3.  Mutational Profiles of F8 and F9 in a Cohort of Haemophilia A and Haemophilia B Patients in the Multi-ethnic Malaysian Population.

Authors:  Maimiza Zahari; Siti Aishah Sulaiman; Zulhabri Othman; Yasmin Ayob; Faraizah Abd Karim; Rahman Jamal
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

4.  Factor 8 Gene Mutation Spectrum of 270 Patients with Hemophilia A: Identification of 36 Novel Mutations

Authors:  Tahir Atik; Esra Işık; Hüseyin Onay; Bilçağ Akgün; Moharram Shamsali; Kaan Kavaklı; Melike Evim; Gülen Tüysüz; Namık Yaşar Özbek; Fahri Şahin; Zafer Salcıoğlu; Canan Albayrak; Yeşim Oymak; Ekrem Ünal; Fatma Burcu Belen; Ebru Yılmaz Keskin; Can Balkan; Birol Baytan; Alphan Küpesiz; Vildan Culha; Tuba Nur Tahtakesen Güçer; Adalet Meral Güneş; Ferda Özkınay
Journal:  Turk J Haematol       Date:  2020-02-06       Impact factor: 1.831

5.  Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.

Authors:  Estelle K Ronayne; Shaun C Peters; Joseph S Gish; Celena Wilson; H Trent Spencer; Christopher B Doering; Pete Lollar; P Clint Spiegel; Kenneth C Childers
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.